Barclays Adjusts Elevance Health (ELV) PT to $393 While Maintaining Overweight Rating

Elevance Health Inc. (NYSE:ELV) is one of the most undervalued large cap stocks to invest in now.. On January 30, Barclays lowered the firm’s price target on Elevance Health to $393 from $404 and kept an Overweight rating on the shares. On January 29, Guggenheim analyst Jason Cassorla also lowered the firm’s price target on Elevance Health to $396 from $414 and maintained a Buy rating on recalibrated 2026 estimates following the company’s Q4 2025 report. However, on the same day, Deutsche Bank raised the ...